Imperial College London

DrDavidErritzoe

Faculty of MedicineDepartment of Brain Sciences

Academic Clinical Lecturer
 
 
 
//

Contact

 

d.erritzoe

 
 
//

Location

 

Neuropsychopharmacology UnitBurlington DanesHammersmith Campus

//

Summary

 

Summary

MD, PhD, MRCPsych, NIHR Academic Clinical Lecturer in General Psychiatry in Neuropsychopharmacology and Psychedelic Research Centres, Division of Psychiatry, Dpt of Brain Sciences, Imperial College London.

Alongside his clinical work in medicine/psychiatry as a post-CCT psychiatrist, David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI. He was trained in PET imaging at Columbia University in New York and later undertook a PhD at University Hospital Rigshospitalet in Copenhagen. Since 2009 he has been involved in post-doc imaging research into the neurobiology of addictions and major depression at Imperial. David has been investigating dopaminergic neurotransmission with measurements of the dopamine D3 receptor in alcohol addiction, studies of opioid neurotransmission in pathological gambling, and functional imaging studies looking at the role of dopamine D3 and mu-opiate receptors in cocaine, alcohol, and heroin addiction. 

Currently, he runs lab-based multi-modal brain imaging studies [often using pharmacological challenges] focusing on serotonin/dopamine/opiate neurotransmission as well as larger-scale prospective, naturalistic studies with online assessments and/or field-based data collection. Specifically, in the Centre for Psychedelic Research [where David is Clinical Director], studies are undertaken together with Prof Nutt and Dr Carhart-Harris, investigating brain mechanisms and therapeutic potential of MDMA and classic psychedelics.

Publications

Journals

Borissova A, Ferguson B, Wall MB, et al., 2020, Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment, Journal of Psychopharmacology, ISSN:0269-8811

Nutt D, Erritzoe D, Carhart-Harris R, 2020, Psychedelic Psychiatry's Brave New World, Cell, Vol:181, ISSN:0092-8674, Pages:24-28

Conference

Erritzoe D, Ashok AH, Searle GE, et al., 2020, Serotonin release measured in the human brain: a PET study with [C-11]CIMBI-36 and d-amphetamine challenge, 28th International Symposium on Cerebral Blood Flow, Metabolism and Function / 13th International Conference on Quantification of Brain Function with PET, NATURE PUBLISHING GROUP, Pages:804-810, ISSN:0893-133X

Erritzoe D, Godlewska BR, Rizzo G, et al., 2019, Brain serotonin release reduced among patients with severe depression: a pet study with [11c]cimbi-36 and d-amphetamine challenge, 32nd Congress of the European-College-of-Neuropsychopharmacology (ECNP), ELSEVIER, Pages:S258-S258, ISSN:0924-977X

Stenbaek D, Madsen MK, Ozenne B, et al., 2019, Modelling the acute temporal dynamics of psilocybin psychoactive effects; relation to brain serotonin 2a receptor levels, 32nd Congress of the European-College-of-Neuropsychopharmacology (ECNP), ELSEVIER, Pages:S558-S558, ISSN:0924-977X

More Publications